We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 08, 2021

Veliparib With Modified FOLFIRI vs FOLFIRI as Second-Line Treatment of Metastatic Pancreatic Cancer

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
Clin. Cancer Res 2021 Sep 27;[EPub Ahead of Print], EG Chiorean, KA Guthrie, PA Philip, EM Swisher, F Jalikis, MJ Pishvaian, J Berlin, MS Noel, JM Suga, I Garrido-Laguna, DB Cardin, MR Radke, M Duong, S Bellasea, AM Lowy, HS Hochster

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading